IRIS
MUSUMECI, FRANCESCA MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.446
Totale 6.446
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 6.446
Totale 6.446
Salva come PNG Salva come JPEG
Città #
Genova 4.326
Genoa 821
Rapallo 812
Vado Ligure 473
Bordighera 14
Totale 6.446
Salva come PNG Salva come JPEG
Nome #
Fyn kinase in brain diseases and cancer: the search for inhibitors. 148
Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma. 140
Analogs, formulations and derivatives of imatinib: A patent review 137
A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors. 133
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma 131
ATP-competitive inhibitors of mTOR: an update. 130
Click Chemistry, A Potent Tool in Medicinal Sciences 129
Src kinase inhibitors: an update on patented compounds 119
In silico identification and biological evaluation of novel selective serum/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold 118
Bcr-Abl tyrosine kinase inhibitors: A patent review 118
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant 118
The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme 118
Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. 116
An update on dual Src/Abl inhibitors 112
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. 110
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors 108
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment 108
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells 107
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. 105
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia 104
Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells 102
CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction. 101
Water Solubility Enhancement of Pyrazolo[3,4-d]pyrimidine Derivatives via Miniaturized Polymer–Drug Microarrays 100
Novel dual Src/Abl inhibitors for hematologic and solid malignancies. 99
Pyrrolo[2,3-d]pyrimidines as kinase inhibitors 98
SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation 97
A1 receptors ligands: past, present and future trends. 94
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction 93
Selective chemical oxidation of risperidone: a straightforward and cost-effective synthesis of paliperidone 92
Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies 92
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. 90
Matrine in association with FD‑2 stimulates F508del‑cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809 89
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model 89
Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors 85
The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells 84
An Update on JAK Inhibitors 82
Hck inhibitors as potential therapeutic agents in cancer and HIV infection 80
Substituted pyrazolo[3,4-b]pyridines as human A(1) adenosine antagonists: Developments in understanding the receptor stereoselectivity 78
3-Cyano-4,6-diphenyl-pyridine amino acid derivatives active as influenza A polymerase inhibitors 78
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives active against the T315I Abl mutation. 77
Starch/Poly(glycerol-adipate) Nanocomposites: A Novel Oral Drug Delivery Device 76
Synthesis of pyrazolo[3,4-d]pyrimidines active on Bcr-Abl T315I mutation. 74
Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors 72
Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors 71
One-pot synthesis of indolyl- pyrrolones as Pim1 inhibitors 70
SGK1 as a new target for anticancer agents: a hit-to-lead study 70
Synthesis of new pyrazolo[3,4-d]pyrimidines 6-alkyl substituted Bcr-Abl tyrosine kinase inhibitors 70
Exploring SAR of a new generation of pyrazolo[3,4-d]pyrimidines as Fyn tyrosine kinase inhibitors 69
Synthesis of a small library of potential SGK1 inihibitors 69
In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity 69
6-Substituted pyrazolo[3,4-d]pyrimidines: new promising compounds in the fight against Neuroblastoma 68
Formulation Of Pyrazolo[3,4-d]pyrimidines Kinase Inhibitors For The Treatment Of Glioblastoma Multiforme 68
Pyrazolo[3,4-d]pyrimidine active on neuroblastoma cells 68
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines 67
Synthesis of heterocyclic compounds to be tested as potentiators or correctors of mutant CFTR in cystic fibrosis 65
The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cells 65
Pyrazolo[3,4-d]pyrimidines as tyrosine kinase inhibitors: synthesis and biological evaluation 64
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives active in a preclinical glioblastoma model. 63
Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists. 62
Synthesis of a new generation of pyrazolo[3,4-d]pyrimidine as SGK-1 inhibitors. 61
Synthesis of a new generation of pyrazolo[3,4-d]pyrimidines as Fyn inhibitors 59
Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4-d]pyrimidines Kinase Inhibitors 59
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives endowed with activity against the T315I Abl mutation 52
Insight into Fyn and SGK1 kinases as new targets in medicinal chemistry: design and synthesis of pyrazolo[3,4-d]pyrimidine libraries 52
The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the64CuCl2in Human Glioblastoma Multiforme Cells 51
Formulated pyrazolo[3,4-d]pyrimidines active on GBM cell lines 51
Identification of a new family of pyrimidine and pyridine derivatives as disruptors of the viral RNA-dependent RNA polymerase 47
Synthesis of a new series of optimized pyrazolo[3,4‑d]pyrimidines as Src Inhibitors 43
null 40
Combining repositioning and de novo synthesis of pyrazolo[3,4-d]pyrimidines to discover potent SIRT-2 inhibitors 38
Insights into RNA-dependent RNA Polymerase Inhibitors as Anti-influenza Virus Agents 38
Design, synthesis, and biological evaluation of a new series of pyrazolo[3,4-d]pyrimidines active as SGK1 inhibitors. A lead optimization study. 37
Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells 35
PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AS SIRTUIN INHIBITORS: DESIGN, SYNTHESIS AND PRELIMINARY in vitro EVALUATION 35
Development of a new potential theranostic prodrug for targeting glioblastoma multiforme 34
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma 33
Synthesis of hybrid small molecules as potential PA-PB1 heterodimer disruptors of Influenza virus Polymerase 32
Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment 28
Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors 28
Synthesis of a new generation of potential anti-influenza agents targeting the PA-PB1 protein-protein interaction. 27
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling 26
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment 25
New potential anti-flu agents acting by disrupting the PA-PB1 interaction of viral polymerase. 25
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment 24
In silico exploration of LANCL2-ABA binding mode towards the identification of novel LANCL2 agonists 23
Design and synthesis of a new series of pyrazolo[3,4- d]pyrimidines active as SGK1 inhibitors in ovarian cancer cell models 21
SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW 4-AMINO-PYRAZOLO[3,4-d]PYRIMIDINES AS POTENTIAL SRC KINASE INHIBITORS 21
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme 18
New Insights into the LANCL2-ABA Binding Mode towards the Evaluation of New LANCL Agonists 16
IN SILICO INVESTIGATION OF LANCL-2 ACTIVATION MECHANISM: THE CASE OF BT-11 (OMILANCOR). 16
A family of nitrogen-containing heterocycles as sirtuin inhibitors: synthesis and invitro biological evaluation 14
Structure-Based Virtual Screening (SBVS) for the discovery of Sirtuin-2 inhibitors 12
Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor 11
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA–PB1 Subunits Interaction 7
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective 7
Sweet Cherry Extract as Permeation Enhancer of Tyrosine Kinase Inhibitors: A Promising Prospective for Future Oral Anticancer Therapies 6
Inhibition of serum- and glucocorticoid-induced kinase 1 ameliorates hydrocephalus in preclinical models 6
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted Therapy 5
Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme 4
Applying molecular hybridization to design a new class of pyrazolo[3,4-d] pyrimidines as Src inhibitors active in hepatocellular carcinoma 3
Totale 6.679
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.783
article - articoli 16.481
book - libri 0
conference - conferenze 6.302
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.566
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.503 0 0 0 0 149 169 280 148 169 300 233 55
2020/2021673 37 39 32 24 51 71 115 56 59 81 49 59
2021/2022891 16 38 77 104 18 76 37 214 75 62 40 134
2022/2023997 95 90 7 133 125 164 0 72 173 8 115 15
2023/2024658 19 76 17 94 45 52 34 25 38 43 66 149
2024/2025512 48 124 89 101 150 0 0 0 0 0 0 0
Totale 6.679